Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) are now a cornerstone of treatment for non-small cell lung cancer (NSCLC). Despite reporting tremendous results for some patients, ICI efficacy remains reserved to a subgroup that is not yet fully characterized. Tissue based assays, such as Programm...

Descripción completa

Detalles Bibliográficos
Autores principales: Duchemann, Boris, Remon, Jordi, Naigeon, Marie, Mezquita, Laura, Ferrara, Roberto, Cassard, Lydie, Jouniaux, Jean Mehdi, Boselli, Lisa, Grivel, Jonathan, Auclin, Edouard, Desnoyer, Aude, Besse, Benjamin, Chaput, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761725/
https://www.ncbi.nlm.nih.gov/pubmed/33287347
http://dx.doi.org/10.3390/cancers12123625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761725/
https://www.ncbi.nlm.nih.gov/pubmed/33287347
http://dx.doi.org/10.3390/cancers12123625

Ejemplares similares